Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA To Review Contractor Workforce In Broad Staffing Assessment

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency's budgeting and prioritization efforts are more difficult because it does not know how much it spends on contractors, GAO notes.

You may also be interested in...



FDA's No-Bid Contracts Could Be Further Reduced, Even With Recent Progress

Agency now awarding 80 percent of eligible contracts competitively.

FDA's No-Bid Contracts Could Be Further Reduced, Even With Recent Progress

Agency now awarding 80 percent of eligible contracts competitively.

FDA's DTC Review Problems Highlight Industry's Growing Legal Squeeze

The Government Accountability Office's report on FDA's staffing and budgeting problems highlights the agency's funding challenge: it's so strapped that it often can't even effectively assess how it's using its resources

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS069721

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel